MedTrace Logo

A Study on the Use of Tanakan® for Recovery of Neurological Impairment Following Ischaemic Stroke

NCT00276380 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 204

Last updated 2019-01-08

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the effectiveness of Tanakan® 240mg in association with Acetylsalicylic acid (325mg/day) in the recovery of neurological impairment following ischemic stroke.

Conditions

  • Stroke, Acute
  • Neurological Impairment

Interventions

DRUG

EGb761

EGb761 (Tanakan) 40 mg tablets (2 tablets t.i.d. (3 times a day)) 240 mg/day for 6 months.

DRUG

Placebo

Placebo 40 mg tablets (2 tablets t.i.d.) 240 mg/day for 6 months.

DRUG

Acetylsalicylic acid

Acetylsalicylic acid 325 mg/day (1 tablet once daily), for 6 months.

Sponsors & Collaborators

Principal Investigators

  • Ipsen Medical Director · Ipsen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-02-28
Primary Completion
2009-03-31
Completion
2009-03-31

Countries

  • Czechia
  • Poland
  • Romania
  • Russia

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00276380 on ClinicalTrials.gov